Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The fireside chat is scheduled for September 16 at 8:30 a.m. EDT and will be webcast live, with a replay available on the Events & Presentations page of Helus Pharma's investor relations website. The full press release can be accessed at https://ibn.fm/r0jfC.
This appearance at a major healthcare investment conference signals growing recognition of Helus Pharma's work in developing proprietary novel serotonergic agonists (NSAs) for mental health conditions. The company, which operates as the commercial name of Cybin Inc., is a clinical-stage pharmaceutical firm focused on addressing the large unmet need for people suffering from depression, anxiety, and other mental health disorders. Its lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Another candidate, HLP004, is in Phase 2 for generalized anxiety disorder. These NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, aiming to provide durable improvements in mental health.
The fireside chat provides an opportunity for investors and analysts to gain insight into Helus Pharma's strategic direction, clinical progress, and the potential of its pipeline. With class-leading data, the company aims to improve the treatment landscape for mental health conditions. The conference, hosted by Morgan Stanley, is a key event for healthcare companies to engage with the investment community, and Helus Pharma's participation underscores its commitment to advancing innovative therapies.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP.
BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, disseminated the announcement. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which offers wire solutions, article and editorial syndication to over 5,000 outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com. Terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
